Referred to the House Committee on Energy and Commerce.
The bill amends the Federal Food, Drug, and Cosmetic Act to allow prompt approval of drugs submitted under 505(b)(2) or 505(j) even when their labeling omits safety information that is protected by exclusivity or patent. It directs the FDA to require that such approved drug labeling include any safety information the Secretary considers necessary to assure safe use.
Liberal emphasizes access and FDA’s role protecting patients
Relative to its intended legislative type, this bill cleanly articulates a targeted statutory change to the drug approval/misbranding framework and ties that change to existing exclusivity and patent provisions, but it leaves key implementation details, definitions, timelines, fiscal considerations, and accountability mechanisms largely unspecified.
The bill amends the Federal Food, Drug, and Cosmetic Act to allow prompt approval of drugs submitted under 505(b)(2) or 505(j) even when their labeling omits safety information that is protected by exclusivity or patent.
It directs the FDA to require that such approved drug labeling include any safety information the Secretary considers necessary to assure safe use.
The bill clarifies that it does not change the availability or scope of certain statutory exclusivities or otherwise alter other protected labeling rights, except as expressly provided.
Technically narrow and administrable but involves contested tradeoffs between patient safety labeling and patent/exclusivity interests, inviting stakeholder opposition.
Relative to its intended legislative type, this bill cleanly articulates a targeted statutory change to the drug approval/misbranding framework and ties that change to existing exclusivity and patent provisions, but it leaves key implementation details, definitions, timelines, fiscal considerations, and accountability mechanisms largely unspecified.
Liberal emphasizes access and FDA’s role protecting patients
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberal emphasizes access and FDA’s role protecting patients
Likely supportive.
The bill appears to reduce tactics that delay generic entry and empowers FDA to ensure safety information is available, increasing access and lowering costs.
It preserves exclusivity language nominally, but the Secretary’s authority to require safety statements is seen as pro-consumer.
Cautiously favorable if clarified.
The bill addresses anti-competitive labeling tactics and speeds access to generics, but raises legal and implementation questions that merit precise guidance and possibly additional resources for FDA enforcement.
Skeptical.
The bill risks encroaching on patent and exclusivity protections and expands FDA authority to alter or require labeling content, raising concerns about regulatory overreach and reduced incentives for drug innovation.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technically narrow and administrable but involves contested tradeoffs between patient safety labeling and patent/exclusivity interests, inviting stakeholder opposition.
The bill has not accumulated any surfaced votes yet.
Liberal emphasizes access and FDA’s role protecting patients
Technically narrow and administrable but involves contested tradeoffs between patient safety labeling and patent/exclusivity interests, inv…
Relative to its intended legislative type, this bill cleanly articulates a targeted statutory change to the drug approval/misbranding framework and ties that change to existing exclusivity and patent provisions, but it…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.